Do concomitant medications affect cosentyx's effectiveness?

What are the guidelines for using Cosentyx with other medications?

The manufacturer of Cosentyx, Novartis, recommends that patients inform their healthcare provider about all medications they are currently taking, including prescription and over-the-counter (OTC) medications [1]. This is because certain medications may interact with Cosentyx, which could affect its effectiveness or increase the risk of side effects.

How does Cosentyx interact with concomitant medications?

Cosentyx may interact with other medications, including blood thinners, immunosuppressants, and other biologics. The effect of these interactions can vary depending on the specific medications and individual patients. According to the Cosentyx prescribing information, patients should not take Cosentyx with live vaccines, as this may increase the risk of live vaccine replication and associated diseases [2].

What should patients do if they are taking concomitant medications?

Patients taking Cosentyx and concomitant medications should monitor their condition closely and report any changes or concerns to their healthcare provider. Regular blood tests, including Complete Blood Counts (CBCs) and liver function tests, may be necessary to monitor for any adverse effects [1].

Effectiveness of Cosentyx in patients taking concomitant medications

There is limited clinical trial data available on the effectiveness of Cosentyx in patients taking concomitant medications. However, a phase 3 trials study [3] demonstrated that Cosentyx was effective in patients with moderate to severe plaque psoriasis who were receiving concomitant methotrexate, but the study did not investigate the effect of multiple concomitant medications.

Sources:

[1] Cosentyx (secukinumab) Prescribing Information. Available from: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyxpi.pdf

[2] Cosentyx (secukinumab) Full Prescribing Information. Novartis Pharmaceuticals Corporation. 2023. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyxpi202306.pdf

[3] Reich et al. Efficacy and safety of secukinumab, a human anti-IL-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis: a phase 3 randomised trial. Lancet. 2012;379(9823):1725.